2-{4-[(2S)-2-hydroxy-3-[(propan-2-yl)amino]propoxy]phenyl}acetamide

• ChemBase ID: 179869
• Molecular Formular: C14H22N2O3
• Molecular Mass: 266.33608
• Monoisotopic Mass: 266.16304257
• SMILES: C(=O)(Cc1ccc(OC[C@@H](CNC(C)C)O)cc1)N
• Canonical SMILES: O[C@@H](COc1ccc(cc1)CC(=O)N)CNC(C)C
• InChI: InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
• InChIKey: METKIMKYRPQLGS-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-{4-[(2S)-2-hydroxy-3-[(propan-2-yl)amino]propoxy]phenyl}acetamide
• IUPAC Traditional name: 2-{4-[(2S)-2-hydroxy-3-[(propan-2-yl)amino]propoxy]phenyl}acetamide
• Synonyms: Atenix; Atenol; Cuxanorm; Myocord; Prenormin; Selobloc; Tenoblock; Tenoretic; Tenormin; Totamol; Vasaten; Atenolol

Database IDs

• CAS Number: 29122-68-7
• PubChem SID: 164235779
• PubChem CID: 180559

CALCULATED PROPERTIES

• Acid pKa: 14.078504
• H Acceptors: 4
• H Donor: 3
• LogD (pH = 5.5): -2.7682068
• LogD (pH = 7.4): -1.8002133
• Log P: 0.42502484
• Molar Refractivity: 73.5053 cm^3
• Polarizability: 29.0903 Å^3
• Polar Surface Area: 84.58 Å^2
• Rotatable Bonds: 8
• Lipinski's Rule of Five: true

PROPERTIES

Pharmacology Properties

• Mechanism of Action: Beta1-receptor specific antagonist; Beta-Adrenergic blocker

Product Information

• Application(s): Antihypertensive agent; Can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, arrhythmias, angina (chest pain) and; to treat and reduce the risk of heart complications following myocardial infarction (heart attack)

REFERENCES

• U.K. Pat., 1975, 1 391 444; CA, 83, 96783v, (synth)
• Brown, H.C. et al., Clin. Pharmacol. Ther. (St. Louis), 1976, 20, 524, (pharmacol)
• Heel, R.C. et al., Drugs, 1979, 17, 425, (rev)
• Fitzgerald, J.D., Pharmacol. Biochem. Prop. Drug Subst., 1979, 2, 98, (rev, pharmacol)
• Marmo, E., Drugs Exp. Clin. Res., 1980, 6, 639, (rev)
• Caplar, V. et al., Acta Pharm. Jugosl., 1983, 33, 71; CA, 99, 187098, (rev, props)
• Robertson, J.I.S. et al., Drugs, Vol. 25, Suppl. 2: -Blockade in the 1980s - Focus on Atenolol, ADIS Press, 1983, (book)
• Caplar, V. et al., Anal. Profiles Drug Subst., 1984, 13, 1, (rev)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 3332, (synonyms)
• Mehvar, R. et al., J. Pharm. Sci., 1990, 79, 881; 1991, 80, 207, (pharmacokinet, isomers)
• Wadworth, A.N. et al., Drugs, 1991, 42, 468, (rev)
• Bevinakatti, H.S. et al., J.O.C., 1992, 57, 6003, (bibl, synth, isomers, pmr, ir)
• Carlsen, P.H.J. et al., Acta Chem. Scand., 1994, 48, 273, (synth, ms)
• Cruickshank, J.M. et al., Beta-blockers in Clinical Practice, 2nd edn., Churchill Livingstone, Edinburgh, 1994, (book)
• Kleidernigg, O.P. et al., Chirality, 1994, 6, 411, (synth, hplc, gc-ms)
• McCoy, R.A. et al., J. Clin. Pharmacol., 1994, 34, 816, (pharmacol, isomers)
• Reid, J.L. et al., Ann. N.Y. Acad. Sci., 1995, 763, 673, (rev)
• Kitaori, K. et al., Chem. Pharm. Bull., 1997, 45, 412; 1998, 46, 505-507, (synth, pmr, cmr)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 825
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, TAL475